Dehydrocorybulbine is an alkaloid isolated from Corydalis yanhusuo. Dehydrocorybulbine binds to the dopamine D1 receptor. Current pain management is limited, in particular, with regard to chronic pain. As part of the "herbalome" project, with the reverse pharmacology approach aimed at discovering new endogenous transmitters and hormones. Dehydrocorybulbine (DHCB), is effective at alleviating thermally induced acute pain. DHCB displays moderate dopamine receptor antagonist activities. By using selective pharmacological compounds and dopamine receptor knockout (KO) mice, DHCB antinociceptive effect is primarily due to its interaction with D2 receptors, at least at low doses. DHCB is effective against inflammatory pain and injury-induced neuropathic pain and furthermore causes no antinociceptive tolerance.